Raghuveer Ramachandra

577 total citations
23 papers, 406 citations indexed

About

Raghuveer Ramachandra is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Raghuveer Ramachandra has authored 23 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Raghuveer Ramachandra's work include Cancer Immunotherapy and Biomarkers (10 papers), Peptidase Inhibition and Analysis (7 papers) and Lung Cancer Research Studies (4 papers). Raghuveer Ramachandra is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Peptidase Inhibition and Analysis (7 papers) and Lung Cancer Research Studies (4 papers). Raghuveer Ramachandra collaborates with scholars based in United States, India and China. Raghuveer Ramachandra's co-authors include Jianbo Yao, Caird E. Rexroad, Murali Ramachandra, Scott A. Gahr, Mohamed Salem, Pottayil G. Sasikumar, Rashmi Nair, Dodderi S. Samiulla, Gao‐Feng Qiu and Jiju Mani and has published in prestigious journals such as Cancer Research, European Journal of Cancer and Molecular Cancer Therapeutics.

In The Last Decade

Raghuveer Ramachandra

21 papers receiving 390 citations

Peers

Countries citing papers authored by Raghuveer Ramachandra

Since Specialization

Citations

This map shows the geographic impact of Raghuveer Ramachandra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raghuveer Ramachandra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raghuveer Ramachandra more than expected).

Fields of papers citing papers by Raghuveer Ramachandra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raghuveer Ramachandra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raghuveer Ramachandra. The network helps show where Raghuveer Ramachandra may publish in the future.

Co-authorship network of co-authors of Raghuveer Ramachandra

This figure shows the co-authorship network connecting the top 25 collaborators of Raghuveer Ramachandra. A scholar is included among the top collaborators of Raghuveer Ramachandra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raghuveer Ramachandra. Raghuveer Ramachandra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structure-activity relationships of thiadiazole agonists of the human secretin receptor 2024 ·SLAS DISCOVERY ·Robert Ardecky, Daniela G. Dengler, Kaleeckal G. Harikumar, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Raghuveer Ramachandra, Eduard Sergienko, Laurence J. Miller	1
2	PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy 2021 ·Communications Biology ·Pottayil G. Sasikumar, (unknown), (unknown), Raghuveer Ramachandra, Dodderi S. Samiulla, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jiju Mani, (unknown), David Joseph, (unknown), Rashmi Nair, Hanudatta S. Atreya, (unknown), Murali Ramachandra	118
3	Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus 2020 ·Journal of Molecular Graphics and Modelling ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), V.C. Suraj, (unknown), (unknown), (unknown), Raghuveer Ramachandra	24
4	A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy 2019 ·Molecular Cancer Therapeutics ·Pottayil G. Sasikumar, Raghuveer Ramachandra, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Dodderi S. Samiulla, Krishnaprasad Subbarao, Rashmi Nair, Rajeev Shrimali, (unknown), Murali Ramachandra	55
5	Abstract 4148: An orally bioavailable small molecule antagonist of TIM-3 signaling pathway shows potent anti-tumor activity 2019 ·Cancer Research ·Pottayil G. Sasikumar, (unknown), Raghuveer Ramachandra, (unknown), (unknown), (unknown), Jiju Mani, Rashmi Nair, (unknown), (unknown), (unknown), Murali Ramachandra	1
6	Abstract B006: Functional antagonism of VSIG8-mediated immune suppression by oral VISTA agents 2018 ·Molecular Cancer Therapeutics ·Pottayil G. Sasikumar, (unknown), Raghuveer Ramachandra, (unknown), (unknown), (unknown), (unknown), Jiju Mani, Rashmi Nair, (unknown), (unknown), (unknown), Murali Ramachandra	10
7	Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer 2017 ·Cancer Immunology Research ·Adam S. Lazorchak, (unknown), (unknown), Pottayil G. Sasikumar, (unknown), (unknown), Raghuveer Ramachandra, (unknown), Sanjeev Giri, (unknown), Murali Ramachandra, David Tuck, Timothy Wyant	9
8	Abstract 1650: Targeting CD47- SIRPα interaction by novel peptide-based antagonists 2017 ·Cancer Research ·Pottayil G. Sasikumar, (unknown), Krishne Gowda, (unknown), (unknown), Rashmi Nair, (unknown), (unknown), (unknown), Kiran Aithal, Raghuveer Ramachandra, Girish Daginakatte, Murali Ramachandra	1
9	Abstract 4861: Oral immune checkpoint antagonists targeting PD-L1/VISTA or PD-L1/Tim3 for cancer therapy 2016 ·Cancer Research ·Pottayil G. Sasikumar, (unknown), (unknown), Dodderi S. Samiulla, Raghuveer Ramachandra, (unknown), (unknown), Jiju Mani, Rashmi Nair, (unknown), (unknown), (unknown), Murali Ramachandra	11
10	Abstract 3070: Potent and selective inhibition of CDK7 by novel covalent inhibitors 2016 ·Cancer Research ·(unknown), (unknown), Subhendu Mukherjee, (unknown), (unknown), Raghuveer Ramachandra, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Thomas Antony, (unknown), (unknown), Girish Daginakatte, Susanta Samajdar, Murali Ramachandra	2
11	Abstract 339: Identification of novel covalent inhibitors of K-Ras G12C that are efficacious in a xenograft model of NSCLC 2016 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), Sreekanth Reddy, (unknown), (unknown), Sunil K. Panigrahi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Raghuveer Ramachandra, (unknown), (unknown), Murali Ramachandra	1
12	Development and in-vitro Evaluation of Reconstitutable Suspension of Flucloxacillin 2016 ·MARMARA PHARMACEUTCAL JOURNAL ·(unknown), (unknown), Raghuveer Ramachandra	5
13	Abstract C190: Potent and selective inhibition of CDK7 by novel covalent inhibitors 2015 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Girish Daginakatte, Subhendu Mukherjee, (unknown), (unknown), Raghuveer Ramachandra, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Thomas Antony, (unknown), Murali Ramachandra, (unknown), Susanta Samajdar	1
14	432 ODM-203, a novel, selective and balanced FGFR and VEGFR inhibitor with strong anti-tumor activity in FGFR- and VEGFR-dependent cancer models 2014 ·European Journal of Cancer ·Tim H. Holmström, Anu‐Maarit Moilanen, Tero Linnanen, Gerd Wohlfahrt, Stefan Karlsson, Riikka Oksala, Timo Korjamo, Mari Björkman, (unknown), (unknown), (unknown), (unknown), Raghuveer Ramachandra, (unknown), (unknown), Murali Ramachandra, Pauliina Kallio	1
15	A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events 2013 ·Journal for ImmunoTherapy of Cancer ·Pottayil G. Sasikumar, Rajeev Shrimali, (unknown), Raghuveer Ramachandra, (unknown), (unknown), (unknown), (unknown), Murali Ramachandra	14
16	Abstract 1231: Equipotent antagonism, transient immune activation and excellent antitumor efficacy with a peptide inhibitor of PD-1 immune check point pathway. 2013 ·Cancer Research ·Pottayil G. Sasikumar, (unknown), Rajeev Shrimali, Raghuveer Ramachandra, (unknown), (unknown), (unknown), Dodderi S. Samiulla, Murali Ramachandra	1
17	Abstract 2850: Demonstration of anti-tumor efficacy in multiple preclinical cancer models using a novel peptide inhibitor (Aurigene-012) of the PD1 signaling pathway 2012 ·Cancer Research ·Pottayil G. Sasikumar, (unknown), Rajeev Shrimali, Krishnaprasad Subbarao, Raghuveer Ramachandra, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Dodderi S. Samiulla, Murali Ramachandra	12
18	Cloning and characterization of microRNAs from rainbow trout (Oncorhynchus mykiss): Their expression during early embryonic development 2008 ·BMC Developmental Biology ·Raghuveer Ramachandra, Mohamed Salem, Scott A. Gahr, Caird E. Rexroad, Jianbo Yao	82
19	Molecular characterization and expression profiles of cyclin B1, B2 and Cdc2 kinase during oogenesis and spermatogenesis in rainbow trout (Oncorhynchus mykiss) 2007 ·Animal Reproduction Science ·Gao‐Feng Qiu, Raghuveer Ramachandra, Caird E. Rexroad, Jianbo Yao	42
20	Identification of OORP‐T, a novel oocyte‐specific gene encoding a protein with a conserved oxysterol binding protein domain in rainbow trout 2006 ·Molecular Reproduction and Development ·Raghuveer Ramachandra, (unknown), Gregory M. Weber, Caird E. Rexroad, Jianbo Yao	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact